ArticleBMC veterinary research2025
PRRSV GP4 subunit vaccine combined with adenovirus heterologous prime-boost immunization strategy induced a significant immune response in mice.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research Progress of GP4 Protein of Porcine Reproductive and Respiratory Syndrome Virus.Veterinary sciences · 2026Review
- Nanobodies Targeting the GP4 Protein Inhibit PRRSV Replication.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe porcine reproductive and respiratory syndrome virus (PRRSV) continues to cause widespread infections in the pig industry worldwide. Currently, multiple PRRSV vaccine candidates are in preclinical or clinical trials, and each has different advantages and limitations. Glycoprotein 4 (GP4) is rich in epitopes, which can induce the body to produce neutralizing antibodies, plays a vital role in causing the host immune response, and is a key target for PRRSV vaccine development. In this study, we developed a novel candidate vaccine immunization strategy combining a subunit vaccine with an adenovirus vector vaccine through prokaryotic and eukaryotic systems expressing GP4.
resultsIn this study, predictive analysis of PRRSV GP4 antigen structures in two expressed modes, and the results showed good antigenicity. The PRRSV GP4 subunit vaccine, as well as the adenovirus vector-based vaccine, were successfully constructed. In the immunization experiment of mouse models, a heterologous primary-boost immunization strategy was implemented: primary immunization with the GP4 subunit vaccine, and boost immunization was followed by an adenovirus vector vaccine. The safety assessment revealed that all candidate vaccine groups demonstrated good safety profiles. With an indirect enzyme-linked immunosorbent assay (ELISA) and neutralizing antibodies, mice in the combined immunization group developed higher levels of PRRSV-specific antibodies with significantly higher neutralizing antibody titers than mice alone. IgG subtype analysis indicated that the proteome favors the Th2-type immune response, while the adenoviral group favors the Th1-type immune response. The secretion levels of cytokines IL-4, IFN-γ, and TNF-α were significantly higher in the serum of the combined immunization group than in the immune group alone. Moreover, the cellular immune response test results showed that the combined immune group significantly enhanced the splenic lymphocyte proliferation capacity, IFN-γ secretion level, and cytokine transcript level. These findings suggest that the heterologous primary-boost immunization strategy of the PRRSV GP4 subunit vaccine developed here, in combination with the adenovirus vaccine, successfully induced strong humoral and cellular immune responses in mice.
conclusionsIn this study, the PRRSV GP4 subunit and adenovirus vector vaccine were successfully constructed and induced high levels of PRRSV-specific neutralizing antibody and cellular immune responses in mouse models by a heterologous primary-boost immunization strategy. These results support the clinical development of the PRRSV vaccine and bring new hope for PRRSV prevention and control strategies in the swine industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.